You are here:
LinkedIn-button

News

Check here for our latest news

Press Release

Intravacc announces formation of Scientific Advisory Board Bilthoven, the Netherlands, 23 February 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced the formation of a Scientific Advisory Board (“SAB”), chaired by Intravacc’s Chief Scientific…

Intravacc announces formation of Scientific Advisory Board
Read more

Press Release

Intravacc neemt moderne pilot productiefaciliteit in gebruik en start concept-design van multifunctionele vaccinfabriek Bilthoven, the Netherlands, 19 februari 2021 – Intravacc, wereldwijd vooraanstaand op het gebied van translationeel onderzoek naar en de ontwikkeling van vaccins, maakt bekend dat haar nieuwe moderne…

Intravacc neemt moderne pilot productiefaciliteit in gebruik en start concept-design van multifunctionele vaccinfabriek
  • Pilotfabriek geschikt voor productie van vaccins in klinische fase I & II onderzoek
  • Consortium werkt plan uit voor nieuwe multifunctionele vaccinfabriek
  • Uitgebreide omgevingsvergunningen maken snelle realisatie mogelijk
Read more

Press Release

Dutch Intravacc starts concept design for multifunctional, high-capacity vaccine plant for national requirement New state-of-the-art pilot vaccine production facility ready for use   Bilthoven, the Netherlands, 19 February 2021 – Intravacc, a world leader in translational research and development of…

Dutch Intravacc starts concept design for multifunctional, high-capacity vaccine plant for national requirement
  • New pilot plant for production of vaccine candidates in clinical phase I & II research
  • Consortium starts concept design for new multifunctional vaccine factory that can produce enough vaccines for the Netherlands during pandemic
  • Extensive environmental permits already in place will enable rapid construction
Read more

Press Release

Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification Bilthoven, the Netherlands, 21 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announces the WHO prequalification for the Sabin-IPV (sIPV)…

Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification
  • sIPV development is part of Intravacc’s contribution to the eradication of polio
  • LG Chem is the first to receive WHO prequalification for the sIPV vaccine
  • LG Chem signed an $80 million contract with UNICEF to supply polio vaccine starting early 2021
Read more

Press Release

Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio Bilthoven, the Netherlands, 19 January 2021 – Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent…

Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio
  • Potentially the first preventive vaccine for coxsackievirus B, a risk factor associated with type 1 diabetes and celiac disease
  • First dosing of PRV-101 in the PROVENT Phase I clinical trial started in January 2021
Read more

Press Release

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms Bilthoven and Maastricht, the Netherlands, 6 January 2021 – Intravacc, a world leader in translational research and development of vaccines, and Cristal Therapeutics,  a technology leader in enabling…

Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
  • First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2
  • Evaluation of Cristal’s CliCr® and Intravacc’s OMV technology
Read more
LinkedIn-button

NEED MORE INFORMATION?

Contact our
specialist

A team of 140+ specialists is at your disposal here in Bilthoven. Contact us to see how we can bring your vaccine concept ready for in-human trials.

CONTACT

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.